During the first quarter of the 2024 earnings season, large drugmakers Bayer and Bristol Myers Squibb announced thousands of layoffs in two of the largest workforce reductions so far this year. Coming off years of upheaval in the biotech and pharma sectors, will this be a temporary bump in the road or the beginning of a significant wave of Big Pharma layoffs?  

Novo Nordisk

The U.S. Food and Drug Administration’s (FDA) staff on Wednesday pointed to “notable imbalance” in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk’s (NOVOb.CO) long-acting weekly insulin.

tug of war, money

Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.


The company announced today that it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.

A large fire that broke out at a Novo Nordisk office building in Denmark on Wednesday has been brought under control, the local fire department said.

Great progress has been made in the management of female infertility since the introduction of assisted reproductive technology, predominantly in vitro fertilization (IVF). However, despite the improvements made in the space, challenges associated with the treatment remain. The development of non-injectable fertility medications represents a significant unmet need, reports GlobalData.

Dr. Reddy's

Under the agreement, Dr. Reddy’s gets exclusive commercialization rights in the United States as well as semi-exclusive rights in Europe and United Kingdom, and Alvotech will be responsible for development and manufacture of the product.


The British-Swedish company on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.


The regulator approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.

The Boston-based drug developer will use its proprietary technology along with Lilly’s expertise in oncology drugs to develop therapies for a range of solid tumors.